Literature DB >> 14614045

Prognostic relevance of mitotic activity in patients with node-negative breast cancer.

Laura Medri1, Annalisa Volpi, Oriana Nanni, Anna Maria Vecci, Annita Mangia, Francesco Schittulli, Franco Padovani, Donata Casadei Giunchi, Alfredo Zito, Alfredo Vito, Dino Amadori, Angelo Paradiso, Rosella Silvestrini.   

Abstract

The prognostic relevance of mitotic activity was analyzed in a series of 306 patients with node-negative breast cancer treated with locoregional therapy alone, until early relapse. Mitotic activity was evaluated as the number of mitotic figures per 10 high-power fields (mitotic activity index) or per 1000 tumor cells (mitotic index). Counting was carried out blindly by two observers. A high correlation was observed between the two determinations (r(s) =.96, P <.001). For clinical analysis, three mitotic activity index subgroups (mitotic figures/field </= 9, 10-19 and more than 19, according to grading criteria) and three mitotic index subgroups (percentage of mitotic figures less than 0.10, 0.11-0.50 and more than 0.50, according to tertile criteria) were considered. No relation was observed between mitotic variables and 6-year disease-free survival, whereas distant disease-free survival was strongly related to mitotic figures per 10 fields (85%, 89% and 70%, P =.012) and to the percentage of mitotic figures out of a total 1000 tumor cells (87%, 86% and 75%, P =.017). Similarly, both mitotic indices were significantly related to 6-year overall survival (99%, 95% and 77%, P <.001, for mitotic figures per 10 fields and 99%, 93% and 82%, P <.001, for the percentage of mitotic figures). These findings were particularly evident in patients with tumors of 1-2 cm. In conclusion, a high number of mitotic figures is associated with a higher probability of developing distant metastases and a shorter survival. The critical point remains the standardization of the preanalytical and analytical steps within quality control programs.

Entities:  

Mesh:

Year:  2003        PMID: 14614045     DOI: 10.1097/01.MP.0000093625.20366.9D

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  The Prognostic Value of E-cadherin Expression in Breast Cancer.

Authors:  Layla Kamal Younis; Hala El Sakka; Imranul Haque
Journal:  Int J Health Sci (Qassim)       Date:  2007-01

2.  Mitotic Index Analysis.

Authors:  Takamitsu A Kato; Jeremy S Haskins
Journal:  Methods Mol Biol       Date:  2023

3.  Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone.

Authors:  Djuana M E Harvell; Jihye Kim; Jenean O'Brien; Aik-Choon Tan; Virginia F Borges; Pepper Schedin; Britta M Jacobsen; Kathryn B Horwitz
Journal:  Horm Cancer       Date:  2013-03-12       Impact factor: 3.869

4.  Reprogramming of fibroblasts from older women with pelvic floor disorders alters cellular behavior associated with donor age.

Authors:  Yan Wen; Prachi Wani; Lu Zhou; Tom Baer; Smruti Madan Phadnis; Renee A Reijo Pera; Bertha Chen
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

5.  Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Authors:  Elvira Montero; Carmen Abreu; Paola Tonino
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.553

6.  C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.

Authors:  Isadora F G Sena; Beatriz G S Rocha; Caroline C Picoli; Gabryella S P Santos; Alinne C Costa; Bryan O P Gonçalves; Ana Paula V Garcia; Maryam Soltani-Asl; Leda M C Coimbra-Campos; Walison N Silva; Pedro A C Costa; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Debora Heller; Geovanni D Cassali; Akiva Mintz; Alexander Birbrair
Journal:  Histochem Cell Biol       Date:  2021-05-18       Impact factor: 4.304

7.  Tumor-Derived Exosomes Enriched by miRNA-124 Promote Anti-tumor Immune Response in CT-26 Tumor-Bearing Mice.

Authors:  Ramazan Rezaei; Kaveh Baghaei; Seyed Mahmoud Hashemi; Mohammad Reza Zali; Hossein Ghanbarian; Davar Amani
Journal:  Front Med (Lausanne)       Date:  2021-04-27

8.  Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.

Authors:  Mohammed A Aleskandarany; Andrew R Green; Ahmed A Benhasouna; Fabricio F Barros; Keith Neal; Jorge S Reis-Filho; Ian O Ellis; Emad A Rakha
Journal:  Breast Cancer Res       Date:  2012-01-06       Impact factor: 6.466

9.  Evaluation of mitotic activity index in breast cancer using whole slide digital images.

Authors:  Shaimaa Al-Janabi; Henk-Jan van Slooten; Mike Visser; Tjeerd van der Ploeg; Paul J van Diest; Mehdi Jiwa
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

10.  Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Authors:  Zhi Hu; Jian-Hua Mao; Christina Curtis; Ge Huang; Shenda Gu; Laura Heiser; Marc E Lenburg; James E Korkola; Nora Bayani; Shamith Samarajiwa; Jose A Seoane; Mark A Dane; Amanda Esch; Heidi S Feiler; Nicholas J Wang; Mary Ann Hardwicke; Sylvie Laquerre; Jeff Jackson; Kenneth W Wood; Barbara Weber; Paul T Spellman; Samuel Aparicio; Richard Wooster; Carlos Caldas; Joe W Gray
Journal:  Breast Cancer Res       Date:  2016-07-01       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.